news
Virus-like particle vaccine protects against RSV vaccine-enhanced respiratory disease
Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory diseases...
List view / Grid view
Vaccine Technology
article
Maternal immunisation
3 March 2016 | By Emmanuel Hanon, Senior Vice President, Head of Vaccines Research & Development, GSK
Here, GSK's Emmanuel Hanon discusses maternal vaccination and how it has emerged as a promising public health strategy...
news
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles
28 October 2015 | By Kate Douetil
GSK’s candidate shingles vaccine is a non-live vaccine and combines gE, a protein found on the virus that causes shingles with an adjuvant system, AS01B, which enhances the immunological response to gE...
news
Calixar and VirPath develop an innovative manufacturing process for high performance influenza vaccines
23 September 2014 | By Andrew Lloyd & Associates
A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines...
article
Using self-amplifying mRNA vaccines to facilitate a rapid response to pandemic influenza
Influenza viruses are members of the Orthomyxoviridae family and are a major cause of respiratory tract disease in humans and many animal species. There are three influenza virus types that cause human disease: A, B and C. Type A are further subtyped based on the antigenicity of the hemagglutinin (HA)…
article
Excipient selection in biologics and vaccines formulation development
19 February 2014 | By M. Babu Medi and Ramesh Chintala, Vaccine Drug Product Development, Merck & Co, Inc and Akhilesh Bhambhani, Novel Adjuvants, Formulation and Delivery Technologies, Merck & Co, Inc.
Excipients are an integral part of pharmaceutical products and play an important role in the formulation development of both small and large molecule pharmaceuticals. The type and extent of excipient use depends on several factors, including the type of active ingredient, route of administration, dosage form, target population and indication…
news
European Commission approves nasal spray vaccine FLUENZ for the prevention of seasonal influenza in children
1 February 2011 | By AstraZeneca
The European Commission has granted marketing authorisation to FLUENZ Influenza Vaccine...
news
FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®
31 January 2011 | By Novartis
The FDA approval of Menveo for use in children 2 to 10 years of age is based on Phase III trial data involving 5,297 participants in that age group...
article
Development of stabilised vaccines with needle-free devices for targeted skin immunisation
16 December 2010 | By Abina M. Crean & Anne C. Moore, School of Pharmacy, University College Cork and Conor O’Mahony, Tyndall National Institute, University College Cork
Vaccination represents the primary public health measure to combat infectious diseases. However, limitations of cold-chain storage, vaccine wastage, hazardous sharps-waste and the requirements for trained personnel add significant and unsustainable financial and logistic costs to immunisation programmes. Developments of needle-free methods should aim to overcome these logistics issues from the…
article
Maintaining vaccine security
20 July 2006 | By Howard Smith, Technical and Commercial Manager, Cambridge Biostability
Ninety per cent of the world’s medical research funding is being spent on just ten per cent of the world’s health problems, mostly those afflicting the residents of wealthy countries.
